Editöre Mektup

Myelodysplastic Syndrome and Artificial Intelligence

Cilt: 15 Sayı: 4 31 Aralık 2024
PDF İndir
TR EN

Myelodysplastic Syndrome and Artificial Intelligence

Öz

In the artificial intelligence that will be used in the diagnosis of MDS, the accuracy rate will increase if the database includes all the factors that are effective in the diagnosis and risk classification as much as possible. Artificial intelligence applications that will be implemented using a database that includes as many factors as possible can guide the clinician in the diagnosis of MDS and even in individual treatment choices. Studies with as many patients as possible are needed on this subject.

Anahtar Kelimeler

Destekleyen Kurum

none

Etik Beyan

none

Teşekkür

none

Kaynakça

  1. Karel D, Valburg C, Woddor N, Nava VE, Aggarwal A. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape. Curr Oncol. 2024;31:1971-93.
  2. Sabile JM, Kaempf A, Tomic K, Manu GP, Swords R, Migdady Y. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS). Leuk Lymphoma. 2023;64:1689-94.
  3. Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi R, Elhadary MR, et al. Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects. Cancers. 2023;16: 65.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Hematolojik Tümörler

Bölüm

Editöre Mektup

Yayımlanma Tarihi

31 Aralık 2024

Gönderilme Tarihi

31 Ekim 2024

Kabul Tarihi

26 Kasım 2024

Yayımlandığı Sayı

Yıl 2024 Cilt: 15 Sayı: 4

Kaynak Göster

APA
Yılmaz, F. (2024). Myelodysplastic Syndrome and Artificial Intelligence. Turkish Journal of Clinics and Laboratory, 15(4), 680-680. https://doi.org/10.18663/tjcl.1577122
AMA
1.Yılmaz F. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. 2024;15(4):680-680. doi:10.18663/tjcl.1577122
Chicago
Yılmaz, Fatma. 2024. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory 15 (4): 680-80. https://doi.org/10.18663/tjcl.1577122.
EndNote
Yılmaz F (01 Aralık 2024) Myelodysplastic Syndrome and Artificial Intelligence. Turkish Journal of Clinics and Laboratory 15 4 680–680.
IEEE
[1]F. Yılmaz, “Myelodysplastic Syndrome and Artificial Intelligence”, TJCL, c. 15, sy 4, ss. 680–680, Ara. 2024, doi: 10.18663/tjcl.1577122.
ISNAD
Yılmaz, Fatma. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory 15/4 (01 Aralık 2024): 680-680. https://doi.org/10.18663/tjcl.1577122.
JAMA
1.Yılmaz F. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. 2024;15:680–680.
MLA
Yılmaz, Fatma. “Myelodysplastic Syndrome and Artificial Intelligence”. Turkish Journal of Clinics and Laboratory, c. 15, sy 4, Aralık 2024, ss. 680-, doi:10.18663/tjcl.1577122.
Vancouver
1.Fatma Yılmaz. Myelodysplastic Syndrome and Artificial Intelligence. TJCL. 01 Aralık 2024;15(4):680-. doi:10.18663/tjcl.1577122


e-ISSN: 2149-8296

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.